实用医学杂志 ›› 2023, Vol. 39 ›› Issue (8): 958-962.doi: 10.3969/j.issn.1006⁃5725.2023.08.007

• 临床研究 • 上一篇    下一篇

不同抗逆转录病毒治疗方案对HIV/AIDS患者CK⁃MB、CK的影响 

祁慧 黄亚雄 周国强 曹静    

  1. 长沙市第一医院感染与免疫科(长沙 410000)

  • 出版日期:2023-04-25 发布日期:2023-04-25
  • 通讯作者: 曹静 E⁃mail:cs1caoj@126.com
  • 基金资助:
    湖南省重点领域研发计划(编号:2020SK21362);湖南省科卫联合项目(编号:2020JJ8102) 

Effects of different antiretroviral therapies on CK ⁃MB and CK in HIV/AIDS patients 

QI Hui,HUANG Yaxiong,ZHOU Guoqiang,CAO Jing.   

  1. Department of Infection and Immunology,Changsha First Hospital,Chang⁃ sha 410000,China
  • Online:2023-04-25 Published:2023-04-25
  • Contact: CAO Jing E⁃mail:cs1caoj@126.com

摘要:

目的 探讨含TDF组、含TAF组和不含TDF、TAF的抗逆转录病毒治疗方案对HIV/AIDS 患者 CK⁃MB、CK的影响。方法 选取2020年6-12月在长沙市第一医院门诊就诊的初治HIV/AIDS患者进行回顾 性分析,分析365例HIV/AIDS患者一般资料,并分别收集基线、12、24、48周CK⁃MB、CK检测结果及基线、48周 心电图、心脏彩超检测结果。结果 365例HIV/AIDS患者中,男326 例,女39例;年龄18 ~ 65岁,平均(32.56 ± 10.20)岁。不同治疗时间段 CK⁃MB 存在差别(F = 26.58,P < 0.05)。不同抗病毒治疗时间段与抗病毒方案 之间存在相互作用(F = 95.57,P < 0.05)。不同抗病毒方案之间CK⁃MB存在差异(F = 174.98,P < 0.05),其中 含TDF组随着治疗时间的延长,CK⁃MB越来越高。而不同治疗时间段,CK不存在差别(F = 3.14,P = 0.07)。 不同抗病毒方案治疗时间段与抗病毒方案之间不存在相互作用(F = 1.81,P = 0.16)。但不同抗病毒方案之间 CK存在差异(F = 4.47,P = 0.01)。不同ART方案基线、48周心电图异常发生率差异无统计学意义(χ2 = 0.58, P = 0.75)、(χ2 = 3.14,P = 0.21)。不同ART方案基线、48周心脏彩超异常发生率差异无统计学意义(χ2 = 1.32, P = 0.52)、(χ2 = 0.58,P = 0.75)。结论 不同抗病毒方案对 HIV/AIDS 患者 CK⁃MB、CK 存在影响,尤其是含 TDF的抗病毒方案对HIV/AIDS患者CK⁃MB的影响较大,但对心电图、心脏彩超无明显影响。

关键词:

艾滋病,  , 抗逆转录病毒治疗,  , 肌酸激酶,  , 心肌型肌酸激酶同工酶

Abstract:

Objective To explore the effects of antiretroviral therapies with TDF or TAF and without TDF and TAF on CK ⁃MB and CK in HIV/AIDS patients. Methods A retrospective analysis was conducted on newly treated HIV/AIDS patients from June 2020 to December 2020 in the outpatient department of Changsha First Hospital. The general data of 365 HIV/AIDS patients were analyzed. Levels of CK ⁃ MB and CK at baseline and weeks 12,24,and 48 were collected respectively,so were the baseline and 48⁃week electrocardiogram and color Doppler echocardiography. Results Among 365 HIV/AIDS patients,326 were male and 39 were female. The aver⁃ age age was(32.56 ± 10.20)years. CK ⁃MB was different in different treatment periods(F = 26.58,P < 0.05). There was interaction between different antiviral treatment periods and antiviral regimens(F = 95.57,P < 0.05). There was a difference in CK⁃MB among different antiviral regimens(F = 174.98,P < 0.05),in which the CK⁃MB in the TDF⁃containing group became higher and higher as the prolonged treatments. There was no difference in CK among different treatment periods(F = 3.14,P = 0.07). There was no interaction between different antiviral regi⁃ mens and antiviral regimens(F = 1.81,P = 0.16). However,there were differences in CK among different antivi⁃ ral regimens(F = 4.47,P = 0.01). There was no statistical difference in the incidence of ECG abnormalities at baseline and week 48 among different ART protocols(χ2 = 0.58,P = 0.75;χ2 = =3.14,P = 0.21). There was no statistical difference in the incidence of cardiac color ultrasound abnormalities at baseline and week 48 between different ART protocols(χ2 = 1.32,P = 0.52;χ2 = 0.58,P = 0.75). Conclusions Different anti⁃virus therapies have impacts on CK ⁃MB and CK in HIV/AIDS patients,especially the TDF ⁃ containing therapy shows a greater impact,but it has no significant impact on ECG and cardiac color ultrasound.

Key words:

AIDS, anti?retroviral therapy, creatine kinase, creatine kinase isoenzyme?MB